Deborah J Levine, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · University Health System. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Levine’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C181690 · Current
Licensed to practise in California · since 2022 · expires 2028-09-30 · University of Arizona College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas M1881Physician License · since 2005 · expires 2023-08-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- University Health SystemSan Antonio, TXAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University Health SystemPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.405, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.388, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.3, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.361, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for University Health System
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.405 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.388 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.3 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.361 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,792 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.7 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.43 (105.5 to 195.36) · 136 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.6 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 162 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 254 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,580 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 6,576 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 6,682 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.61 (0.71 to 4.51) · 2,071 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.22 (0.76 to 3.69) · 678 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.78 (0.51 to 3.05) · 2,029 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.56 (0.92 to 12.2) · 778 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.58 (2.42 to 8.75) · 759 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.12 (0.7 to 3.55) · 509 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0.36 to 1.5) · 6,250 cases | No different | Jul 2022 – Jun 2024 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.547 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 181 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 405 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.8 · 88 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.2 · 189 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -16 · 197 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 395 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.3 to 7.6) · 73 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.9 to 14.9) · 73 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 9.5 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.7) · 492 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 362 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,347 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 59% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$114,833
Medicare paid this office $114,833 for 138 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $43,217 | $106 |
| Critical care, first 30-74 minutes | 28 | $37,749 | $186 |
| Long return visit (40+ min) | 84 | $16,547 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,498 | $155 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 15 | $3,297 | $89 |
See all 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $43,217 | $106 |
| Critical care, first 30-74 minutes | 28 | $37,749 | $186 |
| Long return visit (40+ min) | 84 | $16,547 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,498 | $155 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 15 | $3,297 | $89 |
| Hospital discharge day management, 30 minutes or less | 31 | $2,391 | $72 |
Who their Medicare patients are
138 Original Medicare patients in 2024. Average age 63 · Under 65 41% · Women 46% · Also on Medicaid 42% · Health risk score 4.37. Sicker patients than 9 in 10 peers; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 70% · COPD 61% · Atrial fibrillation 45% · Coronary heart disease 43% · Heart failure 41% · Depression 36% · Dementia 14% · Cancer 12% · Stroke 12%.
The office billed $715,522, Medicare allowed $145,180 and paid $114,833; for 900 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 138 | 900 | 63 | 4.37 | $715,522 | $114,833 |
| 2023 | 131 | 849 | 64 | 3.99 | $554,431 | $104,280 |
| 2022 | 56 | 285 | 65 | 3.58 | $163,534 | $30,741 |
| 2021 | 121 | 284 | 66 | 2.37 | $23,423 | $7,354 |
| 2020 | 50 | 185 | 66 | 3.82 | $45,031 | $13,534 |
| 2019 | 61 | 202 | 65 | 3.08 | $45,049 | $14,118 |
| 2018 | 61 | 127 | 65 | 3.35 | $21,473 | $7,864 |
| 2017 | 100 | 292 | 64 | 3.74 | $49,362 | $18,696 |
| 2016 | 110 | 404 | 63 | 2.75 | $85,389 | $30,278 |
| 2015 | 114 | 423 | 62 | 3.54 | $77,529 | $27,502 |
| 2014 | 122 | 498 | 63 | 3.26 | $115,517 | $40,097 |
| 2013 | 130 | 438 | 62 | 3.09 | $84,180 | $28,390 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $43,039 | $110 |
| Critical care, first 30-74 minutes | 20 | $25,017 | $191 |
| Long return visit (40+ min) | 88 | $16,971 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $3,575 | $73 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 20 | $3,272 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,719 | $160 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $2,033 | $120 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,518 | $76 |
2022: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $16,634 | $93 |
| Critical care, first 30-74 minutes | 12 | $6,204 | $188 |
| Long return visit (40+ min) | 19 | $2,421 | $121 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 11 | $1,813 | $113 |
2021: 9 services
| Return visit (30+ min) | 23 | $2,021 | $78 |
| Test to measure expiratory airflow and volume | 59 | $567 | $7 |
| Test to determine lung volumes using sensors | 27 | $253 | $9 |
| Test for exercise-induced lung stress | 12 | $215 | $18 |
| Test to examine how well the lungs exchange gases | 26 | $180 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | $167 | $8 |
| Test to determine lung volumes using sensors | 15 | $145 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 15 | $124 | $8 |
| Test to examine how well the lungs exchange gases | 13 | $93 | $7 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,160 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,855 | $56 |
| Return visit (30+ min) | 15 | $1,386 | $58 |
| Long return visit (40+ min) | 14 | $1,295 | $76 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,403 | $77 |
| Return visit (30+ min) | 43 | $3,396 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,063 | $52 |
2018: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,052 | $55 |
| Return visit (30+ min) | 32 | $1,947 | $53 |
2017: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $5,160 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,421 | $55 |
| Return visit (30+ min) | 46 | $3,432 | $54 |
| Return visit (30+ min) | 28 | $1,821 | $61 |
| Short return visit (20+ min) | 16 | $575 | $36 |
2016: 5 services
| Critical care, first 30-74 minutes | 16 | $9,098 | $162 |
| Return visit (30+ min) | 74 | $6,697 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $5,898 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,457 | $78 |
| Short return visit (20+ min) | 23 | $980 | $38 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $11,572 | $55 |
| Critical care, first 30-74 minutes | 14 | $7,435 | $155 |
| Return visit (30+ min) | 67 | $5,399 | $52 |
| Short return visit (20+ min) | 32 | $1,233 | $36 |
2014: 5 services
| Critical care, first 30-74 minutes | 23 | $17,783 | $171 |
| Return visit (30+ min) | 87 | $7,751 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $7,159 | $54 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $2,092 | $80 |
| Short return visit (20+ min) | 27 | $1,096 | $38 |
2013: 4 services
| Return visit (30+ min) | 96 | $9,167 | $53 |
| Critical care, first 30-74 minutes | 15 | $7,642 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $7,032 | $52 |
| Short return visit (20+ min) | 30 | $1,230 | $35 |
Medicaid work
$2,295 in 2024
Medicaid paid $2,295 for 46 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 46 | $2,295 |
| 2024 | 46 | 1 | 16 | $2,295 |
| 2023 | 314 | 2 | 25 | $8,428 |
| 2022 | 32 | 1 | 12 | $1,181 |
| 2021 | 177 | 3 | 24 | $1,310 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 229 | $5,723 |
| Long return visit (40+ min) | 85 | $2,704 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 32 | $1,181 |
2021
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 65 | $560 |
| EVALUATION OF WHEEZING | 56 | $391 |
| Diffusing capacity | 56 | $360 |
Drugs they prescribed that Part D paid
$516,985
Pharmacies billed $516,985 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,335) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
1,160 generic and fewer than 11 brand-name prescriptions · $516,985 in drug cost · 129 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cresemba | 24 | $147,776 | $6,157 |
| Prevymis | 12 | $95,910 | $7,992 |
| Posaconazole | 60 | $65,252 | $1,088 |
| Everolimus | 20 | $24,602 | $1,230 |
| Itraconazole | 53 | $22,601 | $426 |
See all 32 drugs
| Cresemba | 24 | $147,776 | $6,157 |
| Prevymis | 12 | $95,910 | $7,992 |
| Posaconazole | 60 | $65,252 | $1,088 |
| Everolimus | 20 | $24,602 | $1,230 |
| Itraconazole | 53 | $22,601 | $426 |
| Eliquis | 25 | $19,976 | $799 |
| Valganciclovir | 78 | $13,145 | $169 |
| Atovaquone | 24 | $10,834 | $451 |
| Breo Ellipta | 17 | $6,544 | $385 |
| Tacrolimus | 58 | $4,887 | $84 |
| Advair Diskus | 12 | $2,362 | $197 |
| Sps | 12 | $1,665 | $139 |
| Mycophenolate Mofetil | 26 | $1,547 | $60 |
| Acyclovir | 81 | $1,050 | $13 |
| Ventolin Hfa | 14 | $682 | $49 |
| Rosuvastatin | 50 | $648 | $13 |
| Mirtazapine | 40 | $638 | $16 |
| Pantoprazole | 62 | $587 | $9 |
| Prednisone | 79 | $564 | $7 |
| Azithromycin | 30 | $500 | $17 |
| Sulfamethoxazole-Trimethoprim | 73 | $272 | $4 |
| Metoclopramide | 16 | $250 | $16 |
| Warfarin | 18 | $240 | $13 |
| Tamsulosin | 14 | $206 | $15 |
| Amlodipine Besylate | 55 | $183 | $3 |
| Metoprolol | 54 | $167 | $3 |
| Carvedilol | 16 | $88 | $5 |
| Famotidine | 22 | $85 | $4 |
| Pravastatin | 15 | $44 | $3 |
| Finasteride | 12 | $29 | $2 |
| Citalopram Hbr | 11 | $17 | $2 |
| Amoxicillin | 13 | $13 | $1 |
Year by year
| 2024 | 1,335 | 152 | 0% (0) | None | $516,985 |
| 2023 | 641 | 103 | 0% (0) | 15% | $858,365 |
| 2022 | 407 | 57 | 0% (0) | 39% | $2,504,570 |
| 2021 | 682 | 70 | None | None | $3,529,247 |
| 2020 | 1,097 | 109 | None | None | $3,876,156 |
| 2019 | 1,538 | 149 | 1% (17) | 28% | $3,646,978 |
| 2018 | 1,494 | 142 | None | None | $3,804,545 |
| 2017 | 1,748 | 154 | 1% (12) | 34% | $4,010,314 |
| 2016 | 1,683 | 140 | 1% (19) | 37% | $3,585,452 |
| 2015 | 1,956 | 137 | 1% (27) | 43% | $3,918,387 |
| 2014 | 2,244 | 135 | 1% (32) | 47% | $4,083,347 |
| 2013 | 1,786 | 116 | 2% (27) | 53% | $3,556,495 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Cresemba | 28 | $241,127 | $8,612 |
| Uptravi | 12 | $235,031 | $19,586 |
| Posaconazole | 26 | $93,805 | $3,608 |
| Valganciclovir | 56 | $14,040 | $251 |
| Everolimus | 13 | $13,812 | $1,062 |
| Itraconazole | 24 | $9,775 | $407 |
| Sildenafil Citrate | 15 | $5,060 | $337 |
| Tacrolimus | 19 | $1,373 | $72 |
| Dofetilide | 11 | $623 | $57 |
| Mycophenolate Mofetil | 11 | $601 | $55 |
| Mirtazapine | 22 | $578 | $26 |
| Sulfamethoxazole-Trimethoprim | 49 | $566 | $12 |
| Acyclovir | 43 | $539 | $13 |
| Prednisone | 37 | $274 | $7 |
| Pantoprazole | 19 | $225 | $12 |
| Rosuvastatin | 12 | $199 | $17 |
| Azithromycin | 15 | $187 | $12 |
| Amlodipine Besylate | 12 | $83 | $7 |
| Metoprolol | 16 | $41 | $3 |
2022: 9 drugs
| Uptravi | 33 | $698,552 | $21,168 |
| Opsumit | 50 | $660,109 | $13,202 |
| Ambrisentan | 73 | $330,020 | $4,521 |
| Letairis | 25 | $304,967 | $12,199 |
| Orenitram Er | 15 | $161,136 | $10,742 |
| Tadalafil | 43 | $57,813 | $1,344 |
| Adcirca | 13 | $54,003 | $4,154 |
| Sildenafil Citrate | 90 | $35,852 | $398 |
| Pantoprazole | 13 | $322 | $25 |
2021: 15 drugs
| Uptravi | 47 | $944,440 | $20,094 |
| Opsumit | 67 | $810,708 | $12,100 |
| Letairis | 37 | $414,634 | $11,206 |
| Ambrisentan | 83 | $377,511 | $4,548 |
| Orenitram Er | 35 | $367,435 | $10,498 |
| Remodulin | 12 | $181,531 | $15,128 |
| Prolastin C | 12 | $147,560 | $12,297 |
| Adcirca | 22 | $92,940 | $4,225 |
| Tadalafil | 67 | $82,768 | $1,235 |
| Sildenafil Citrate | 112 | $33,872 | $302 |
| Valganciclovir | 13 | $8,207 | $631 |
| Pantoprazole | 32 | $408 | $13 |
| Potassium Chloride | 14 | $377 | $27 |
| Sulfamethoxazole-Trimethoprim | 19 | $240 | $13 |
| Furosemide | 13 | $40 | $3 |
2020: 24 drugs
| Opsumit | 94 | $1,060,329 | $11,280 |
| Uptravi | 57 | $993,637 | $17,432 |
| Ambrisentan | 92 | $392,501 | $4,266 |
| Letairis | 30 | $288,486 | $9,616 |
| Orenitram Er | 24 | $236,569 | $9,857 |
| Arikayce | 12 | $137,707 | $11,476 |
| Adcirca | 23 | $83,784 | $3,643 |
| Cresemba | 15 | $80,989 | $5,399 |
| Posaconazole | 11 | $72,884 | $6,626 |
| Valganciclovir | 44 | $36,213 | $823 |
| Tadalafil | 54 | $34,351 | $636 |
| Alyq | 11 | $24,969 | $2,270 |
| Sildenafil Citrate | 143 | $24,929 | $174 |
| Cefoxitin | 28 | $18,818 | $672 |
| Advair Diskus | 12 | $4,978 | $415 |
| Tacrolimus | 20 | $4,064 | $203 |
| Pantoprazole | 54 | $1,039 | $19 |
| Azithromycin | 27 | $935 | $35 |
| Sulfamethoxazole-Trimethoprim | 61 | $567 | $9 |
| Metoprolol | 50 | $474 | $9 |
| Rosuvastatin | 15 | $327 | $22 |
| Prednisone | 26 | $276 | $11 |
| Potassium Chloride | 12 | $217 | $18 |
| Furosemide | 25 | $78 | $3 |
2019: 29 drugs
| Uptravi | 67 | $1,023,587 | $15,277 |
| Letairis | 100 | $968,498 | $9,685 |
| Opsumit | 64 | $623,165 | $9,737 |
| Ambrisentan | 39 | $177,943 | $4,563 |
| Adcirca | 40 | $163,036 | $4,076 |
| Tadalafil | 68 | $156,375 | $2,300 |
| Cresemba | 20 | $103,285 | $5,164 |
| Valganciclovir | 77 | $59,422 | $772 |
| Sildenafil Citrate | 160 | $27,727 | $173 |
| Atovaquone | 13 | $22,553 | $1,735 |
| Enoxaparin | 16 | $9,163 | $573 |
| Tacrolimus | 49 | $5,787 | $118 |
| Levemir Flextouch | 12 | $5,593 | $466 |
| Advair Diskus | 11 | $4,431 | $403 |
| Mycophenolate Mofetil | 28 | $3,185 | $114 |
| Esomeprazole Magnesium | 12 | $1,576 | $131 |
| Azithromycin | 22 | $1,358 | $62 |
| Pantoprazole | 91 | $1,211 | $13 |
| Prednisone | 85 | $1,083 | $13 |
| Sulfamethoxazole-Trimethoprim | 99 | $796 | $8 |
| Metoprolol | 67 | $605 | $9 |
| Rosuvastatin | 20 | $363 | $18 |
| Potassium Chloride | 20 | $341 | $17 |
| Acyclovir | 15 | $239 | $16 |
| Furosemide | 25 | $229 | $9 |
| Atorvastatin | 24 | $196 | $8 |
| Ranitidine | 12 | $113 | $9 |
| Tramadol | 13 | $70 | $5 |
| Amoxicillin | 11 | $15 | $1 |
2018: 24 drugs
| Letairis | 146 | $1,356,883 | $9,294 |
| Uptravi | 67 | $1,223,355 | $18,259 |
| Adcirca | 105 | $411,706 | $3,921 |
| Opsumit | 23 | $211,193 | $9,182 |
| Revatio | 12 | $184,498 | $15,375 |
| Valganciclovir | 65 | $67,786 | $1,043 |
| Sildenafil | 183 | $53,761 | $294 |
| Tadalafil | 11 | $36,339 | $3,304 |
| Atovaquone | 21 | $22,876 | $1,089 |
| Advair Diskus | 21 | $9,370 | $446 |
| Tacrolimus | 65 | $7,618 | $117 |
| Enoxaparin | 11 | $3,194 | $290 |
| Esomeprazole Magnesium | 20 | $2,573 | $129 |
| Mycophenolate Mofetil | 16 | $2,351 | $147 |
| Azithromycin | 34 | $1,659 | $49 |
| Pantoprazole | 96 | $941 | $10 |
| Prednisone | 77 | $824 | $11 |
| Sulfamethoxazole-Trimethoprim | 101 | $748 | $7 |
| Potassium Chloride | 32 | $650 | $20 |
| Metoprolol | 61 | $446 | $7 |
| Rosuvastatin | 13 | $438 | $34 |
| Furosemide | 23 | $236 | $10 |
| Atorvastatin | 15 | $199 | $13 |
| Amlodipine Besylate | 13 | $98 | $8 |
2017: 31 drugs
| Letairis | 179 | $1,584,556 | $8,852 |
| Uptravi | 49 | $819,021 | $16,715 |
| Adcirca | 130 | $502,470 | $3,865 |
| Tracleer | 19 | $198,904 | $10,469 |
| Revatio | 12 | $177,574 | $14,798 |
| Valganciclovir | 81 | $132,472 | $1,635 |
| Sildenafil | 161 | $103,786 | $645 |
| Opsumit | 12 | $101,898 | $8,491 |
| Sporanox | 12 | $20,941 | $1,745 |
| Voriconazole | 12 | $16,830 | $1,403 |
| Atovaquone | 18 | $11,310 | $628 |
| Tacrolimus | 62 | $10,650 | $172 |
| Entecavir | 13 | $7,119 | $548 |
| Enoxaparin | 19 | $6,909 | $364 |
| Mycophenolate Mofetil | 50 | $6,021 | $120 |
| Nexium | 13 | $5,372 | $413 |
| Esomeprazole Magnesium | 16 | $5,316 | $332 |
| Pantoprazole | 128 | $1,227 | $10 |
| Sulfamethoxazole-Trimethoprim | 135 | $1,049 | $8 |
| Prednisone | 101 | $1,048 | $10 |
| Azithromycin | 22 | $936 | $43 |
| Rosuvastatin | 16 | $547 | $34 |
| Metoprolol | 82 | $524 | $6 |
| Potassium Chloride | 25 | $520 | $21 |
| Atorvastatin | 19 | $256 | $13 |
| Furosemide | 38 | $177 | $5 |
| Gabapentin | 15 | $132 | $9 |
| Ranitidine | 11 | $110 | $10 |
| Escitalopram | 13 | $103 | $8 |
| Sertraline | 15 | $84 | $6 |
| Amlodipine Besylate | 24 | $70 | $3 |
2016: 28 drugs
| Letairis | 219 | $1,777,552 | $8,117 |
| Adcirca | 156 | $513,139 | $3,289 |
| Revatio | 36 | $348,568 | $9,682 |
| Tracleer | 24 | $229,389 | $9,558 |
| Sildenafil | 133 | $133,149 | $1,001 |
| Valganciclovir | 50 | $116,347 | $2,327 |
| Opsumit | 12 | $92,906 | $7,742 |
| Sporanox | 13 | $16,753 | $1,289 |
| Atovaquone | 15 | $13,153 | $877 |
| Nexium | 17 | $6,873 | $404 |
| Tacrolimus | 42 | $4,652 | $111 |
| Mycophenolate Mofetil | 37 | $2,946 | $80 |
| Prednisone | 103 | $1,132 | $11 |
| Pantoprazole | 107 | $1,081 | $10 |
| Sulfamethoxazole-Trimethoprim | 118 | $1,078 | $9 |
| Potassium Chloride | 26 | $725 | $28 |
| Metoprolol | 95 | $559 | $6 |
| Escitalopram | 11 | $391 | $36 |
| Bd Ultra-Fine Pen Needle | 11 | $390 | $35 |
| Acyclovir | 15 | $371 | $25 |
| Azithromycin | 13 | $288 | $22 |
| Finasteride | 17 | $266 | $16 |
| Ranitidine | 24 | $241 | $10 |
| Atorvastatin | 20 | $217 | $11 |
| Furosemide | 43 | $202 | $5 |
| Gabapentin | 14 | $168 | $12 |
| Tramadol | 14 | $69 | $5 |
| Amlodipine Besylate | 13 | $31 | $2 |
2015: 37 drugs
| Letairis | 267 | $1,895,107 | $7,098 |
| Adcirca | 169 | $455,848 | $2,697 |
| Tracleer | 38 | $321,196 | $8,453 |
| Revatio | 38 | $312,515 | $8,224 |
| Valganciclovir | 77 | $283,148 | $3,677 |
| Tyvaso | 11 | $156,908 | $14,264 |
| Sildenafil | 119 | $87,120 | $732 |
| Opsumit | 11 | $81,406 | $7,401 |
| Atovaquone | 44 | $65,337 | $1,485 |
| Valcyte | 19 | $58,575 | $3,083 |
| Sporanox | 24 | $30,592 | $1,275 |
| Enoxaparin | 16 | $12,468 | $779 |
| Nexium | 18 | $11,324 | $629 |
| Novolog Flexpen | 17 | $7,041 | $414 |
| Crestor | 19 | $5,367 | $282 |
| Mycophenolate Mofetil | 50 | $4,976 | $100 |
| Levemir Flextouch | 11 | $4,136 | $376 |
| Tacrolimus | 32 | $4,020 | $126 |
| Potassium Chloride | 37 | $1,530 | $41 |
| Pantoprazole | 88 | $1,510 | $17 |
| Prednisone | 108 | $1,155 | $11 |
| Sulfamethoxazole-Trimethoprim | 119 | $1,126 | $9 |
| Azithromycin | 18 | $800 | $44 |
| Bd Ultra-Fine Pen Needle | 16 | $605 | $38 |
| Atorvastatin | 41 | $483 | $12 |
| Metoprolol | 94 | $472 | $5 |
| Acyclovir | 15 | $396 | $26 |
| Omeprazole | 20 | $380 | $19 |
| Enalapril Maleate | 11 | $233 | $21 |
| Fluticasone Propionate | 17 | $223 | $13 |
| Levothyroxine | 11 | $216 | $20 |
| Furosemide | 40 | $195 | $5 |
| Ranitidine | 20 | $157 | $8 |
| Spironolactone | 13 | $152 | $12 |
| Zolpidem | 12 | $142 | $12 |
| Tramadol | 22 | $136 | $6 |
| Amlodipine Besylate | 14 | $50 | $4 |
2014: 43 drugs
| Letairis | 242 | $1,613,951 | $6,669 |
| Valcyte | 148 | $612,436 | $4,138 |
| Adcirca | 160 | $361,954 | $2,262 |
| Tracleer | 47 | $359,494 | $7,649 |
| Revatio | 46 | $349,786 | $7,604 |
| Sildenafil | 83 | $113,168 | $1,363 |
| Noxafil | 12 | $110,886 | $9,240 |
| Opsumit | 11 | $77,327 | $7,030 |
| Mepron | 23 | $56,302 | $2,448 |
| Voriconazole | 27 | $53,513 | $1,982 |
| Atovaquone | 31 | $50,211 | $1,620 |
| Sporanox | 22 | $26,257 | $1,194 |
| Enoxaparin | 20 | $18,716 | $936 |
| Nexium | 33 | $17,672 | $536 |
| Tacrolimus | 46 | $10,580 | $230 |
| Mycophenolate Mofetil | 53 | $4,932 | $93 |
| Novolog Flexpen | 13 | $4,525 | $348 |
| Crestor | 11 | $3,184 | $289 |
| Pantoprazole | 117 | $2,299 | $20 |
| Prednisone | 114 | $1,595 | $14 |
| Azithromycin | 40 | $1,575 | $39 |
| Potassium Chloride | 35 | $1,358 | $39 |
| Sulfamethoxazole-Trimethoprim | 134 | $1,138 | $8 |
| Metoprolol | 117 | $751 | $6 |
| Atorvastatin | 40 | $691 | $17 |
| Klor-Con M20 | 12 | $654 | $55 |
| Omeprazole | 33 | $643 | $19 |
| Bd Ultra-Fine Pen Needle | 13 | $504 | $39 |
| Amikacin Sulfate | 12 | $469 | $39 |
| Tamsulosin | 24 | $403 | $17 |
| Fluticasone Propionate | 12 | $225 | $19 |
| Klor-Con 10 | 12 | $213 | $18 |
| Hydrocodone-Acetaminophen | 18 | $192 | $11 |
| Spironolactone | 18 | $178 | $10 |
| Zolpidem | 27 | $156 | $6 |
| Furosemide | 34 | $155 | $5 |
| Alprazolam | 14 | $128 | $9 |
| Ranitidine | 17 | $123 | $7 |
| Enalapril Maleate | 12 | $103 | $9 |
| Tramadol | 12 | $92 | $8 |
| Warfarin | 13 | $73 | $6 |
| Lisinopril | 11 | $60 | $5 |
| Fluoxetine | 12 | $55 | $5 |
2013: 33 drugs
| Letairis | 252 | $1,611,796 | $6,396 |
| Valcyte | 103 | $416,212 | $4,041 |
| Revatio | 58 | $340,137 | $5,864 |
| Tracleer | 47 | $324,331 | $6,901 |
| Adcirca | 179 | $320,875 | $1,793 |
| Tyvaso | 12 | $187,833 | $15,653 |
| Sildenafil | 83 | $134,183 | $1,617 |
| Mepron | 22 | $37,129 | $1,688 |
| Voriconazole | 14 | $22,850 | $1,632 |
| Enoxaparin | 16 | $18,868 | $1,179 |
| Sporanox | 15 | $15,865 | $1,058 |
| Nexium | 30 | $13,595 | $453 |
| Tacrolimus | 27 | $11,133 | $412 |
| Itraconazole | 11 | $8,396 | $763 |
| Mycophenolate Mofetil | 42 | $4,909 | $117 |
| Clonidine | 12 | $1,710 | $142 |
| Atorvastatin | 44 | $1,600 | $36 |
| Pantoprazole | 72 | $1,133 | $16 |
| Azithromycin | 19 | $1,014 | $53 |
| Sulfamethoxazole-Trimethoprim | 122 | $923 | $8 |
| Omeprazole | 22 | $547 | $25 |
| Prednisone | 72 | $484 | $7 |
| Metoprolol | 56 | $452 | $8 |
| Fluticasone Propionate | 15 | $439 | $29 |
| Potassium Chloride | 19 | $424 | $22 |
| Ulticare | 14 | $423 | $30 |
| Klor-Con M20 | 18 | $420 | $23 |
| Hydrocodone-Acetaminophen | 15 | $256 | $17 |
| Zolpidem | 36 | $219 | $6 |
| Alprazolam | 15 | $135 | $9 |
| Furosemide | 24 | $128 | $5 |
| Tramadol | 12 | $109 | $9 |
| Enalapril Maleate | 12 | $66 | $5 |
Money from drug and device companies
$3,992 in 2025
| 2025 | 5 | 9 | $3,400 | $3,992 |
| 2024 | 5 | 23 | $10,047 | $21,990 |
| 2023 | 4 | 17 | $7,046 | $10,859 |
| 2022 | 5 | 25 | $9,568 | $14,022 |
| 2021 | 5 | 19 | $17,710 | $18,721 |
| 2020 | 4 | 38 | $23,923 | $27,654 |
| 2019 | 5 | 83 | $57,900 | $68,911 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| United Therapeutics | Tyvaso | $3,147 | 3 payments
|
| Pierre Fabre Pharmaceuticals | None | $602 | 2 payments
|
| Kamada | Cytogam | $116 | 2 payments
|
| Therakos | None | $92 | 1 payment
|
| La Jolla Pharmaceutical | Giapreza | $34 | 1 payment
|
See all 9 published payments
| La Jolla Pharmaceutical | Meals · 2025-08-04 | Giapreza | $34 |
| United Therapeutics | Consulting · 2025-08-01 | Tyvaso | $2,900 |
| United Therapeutics | Meals · 2025-07-31 | None | $120 |
| Therakos | Meals · 2025-06-10 | None | $92 |
| Kamada | Meals · 2025-05-17 | Cytogam | $79 |
| United Therapeutics | Meals · 2025-05-08 | Tyvaso | $127 |
| Pierre Fabre Pharmaceuticals | Honoraria · 2025-02-27 | None | $500 |
| Pierre Fabre Pharmaceuticals | Meals · 2025-02-27 | None | $102 |
| Kamada | Meals · 2025-01-21 | Cytogam | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $21,990
| Merck Sharp & Dohme | Winrevair | $12,256 | 7 payments
|
| Zambon USA | None | $6,788 | 8 payments
|
| Kamada | Cytogam | $2,550 | 1 payment
|
| Paragonix Technologies | Sherpapak | $282 | 4 payments
|
| United Therapeutics | Steen Solution | $114 | 3 payments
|
2023: $10,859
| Zambon USA | None | $9,449 | 13 payments
|
| Merck Sharp & Dohme | None | $1,315 | 1 payment
|
| United Therapeutics | Tyvaso | $55 | 2 payments
|
| Kamada | Cytogam | $39 | 1 payment
|
2022: $14,022
| Zambon USA | None | $10,096 | 12 payments
|
| Insmed | Arikayce | $2,313 | 2 payments
|
| Sanofi-Aventis U.S. | None | $1,276 | 3 payments
|
| United Therapeutics | Tyvaso | $321 | 7 payments
|
| Actelion Pharmaceuticals US | None | $17 | 1 payment
|
2021: $18,721
| Actelion Pharmaceuticals US | Uptravi | $10,613 | 4 payments
|
| Insmed | Arikayce | $3,941 | 8 payments
|
| United Therapeutics | Tyvaso | $2,175 | 5 payments
|
| One Lambda | None | $1,500 | 1 payment
|
| Vertex Pharmaceuticals | None | $492 | 1 payment
|
2020: $27,654
| Insmed | Arikayce | $17,906 | 34 payments
|
| Actelion Pharmaceuticals US | Uptravi | $4,798 | 1 payment
|
| United Therapeutics | Orenitram | $2,950 | 2 payments
|
| GlaxoSmithKline | None | $2,000 | 1 payment
|
2019: $68,911
| Insmed | Arikayce | $54,320 | 74 payments
|
| Actelion Pharmaceuticals US | Uptravi | $12,718 | 4 payments
|
| One Lambda | None | $1,662 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $150 | 1 payment
|
| United Therapeutics | Orenitram | $62 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019 | Their institution | $20,494 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019 | Their institution | $15,022 |
| Actelion Pharmaceuticals, Ltd · Trace · 2019 | Their institution | $11,336 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020 | Their institution | $6,776 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2021 | Their institution | $4,295 |
| United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2021 | Their institution | $3,629 |
| Biotest AG · Igm/Iga · 2019 | Their institution | $2,819 |
| United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020 | Their institution | $631 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1831206804
- Licence
- CA C181690, TX M1881California C181690: Current · expires 2028-09-30Texas M1881: Canc Non-Renewal
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 162605301
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-24
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4502 Medical Dr, San Antonio, TX, 78229 · 8300 Floyd Curl Dr, San Antonio, TX, 78229